Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
REGULATORY
Ex-Novartis Employee, Japan Unit Indicted over Diovan Data Manipulation
Tokyo prosecutors indicted a former employee of Novartis Pharma and the local arm of Swiss healthcare giant Novartis AG for an alleged violation of the Pharmaceutical Affairs Law (PAL) on July 1, local media reported. The special investigation squad of…
To read the full story
Related Article
- Court Finds Data Manipulation, but Not False Advertising: Diovan Case
March 17, 2017
- Novartis, Ex-Employee Found Not Guilty in Diovan Case
March 16, 2017
- Diovan Data Manipulation Case Closed, Ruling Due Out in March
December 16, 2016
- Prosecutors Seek 2.5 Years in Jail for Ex-Novartis Employee: Diovan Case
November 28, 2016
- Ex-Novartis Employee Pleads Not Guilty over Diovan Data Manipulation
December 17, 2015
REGULATORY
- LDP Biosimilar Group Submits Request to Finance Minister, Seeks Continued Support
December 16, 2025
- LDP’s Patch League Urges Finance Minister to Continue Coverage, Support Prices
December 16, 2025
- Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests
December 15, 2025
- LDP Leans Towards “Special Charges” for OTC-Like Drugs, Not Coverage Removal
December 15, 2025
- Ishin Urges “Special Charge” Scheme for OTC-Like Drugs, Eyes FY2026 Launch
December 15, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…